CO2021010751A2 - Vacuna de influenza atenuada en vivo composición y proceso de preparación de los mismos - Google Patents

Vacuna de influenza atenuada en vivo composición y proceso de preparación de los mismos

Info

Publication number
CO2021010751A2
CO2021010751A2 CONC2021/0010751A CO2021010751A CO2021010751A2 CO 2021010751 A2 CO2021010751 A2 CO 2021010751A2 CO 2021010751 A CO2021010751 A CO 2021010751A CO 2021010751 A2 CO2021010751 A2 CO 2021010751A2
Authority
CO
Colombia
Prior art keywords
laiv
live attenuated
strains
influenza vaccine
attenuated influenza
Prior art date
Application number
CONC2021/0010751A
Other languages
English (en)
Inventor
Rajeev Mhalasakant Dhere
Leena Ravindra Yeolekar
Milan Shomenath Ganguly
Parikshit Dharampal Tyagi
Umesh Gorakh Sagar
Swapnil Prabhakar Narale
Yashodhan Dilip Anaspure
Sham Ramdas Tupe
Original Assignee
Serum Inst Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst Of India Pvt Ltd filed Critical Serum Inst Of India Pvt Ltd
Publication of CO2021010751A2 publication Critical patent/CO2021010751A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona composiciones y métodos para fabricar y obtener una composición de vacuna viva atenuada contra la influenza (LAIV) que puede administrarse por vía intranasal para proporcionar protección contra la infección por el virus de la influenza. Dichas cepas LAIV se basan en fenotipos adaptados al frío, sensibles a la temperatura y atenuados de virus donantes principales (MDV) que contienen los genes de glucoproteína de superficie de las cepas de influenza pandémica o estacional de tipo salvaje. Además, dichas cepas LAIV se adaptan aún más para crecer en células MDCK (células de riñón canino Madin Darby). Se evita el uso de huevos en la fabricación de vacunas a gran escala. El proceso de purificación carece de etapas de cromatografía. Dicha composición LAIV incluye uno o más virus de vacuna contra la Influenza atenuados vivos y carece de polímeros y tensioactivos.
CONC2021/0010751A 2019-02-15 2021-08-13 Vacuna de influenza atenuada en vivo composición y proceso de preparación de los mismos CO2021010751A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921006071 2019-02-15
PCT/IN2020/050121 WO2020165912A1 (en) 2019-02-15 2020-02-07 Live attenuated influenza vaccine composition and process for preparation thereof

Publications (1)

Publication Number Publication Date
CO2021010751A2 true CO2021010751A2 (es) 2021-09-09

Family

ID=69740470

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0010751A CO2021010751A2 (es) 2019-02-15 2021-08-13 Vacuna de influenza atenuada en vivo composición y proceso de preparación de los mismos

Country Status (20)

Country Link
US (1) US20220211837A1 (es)
EP (1) EP3924052A1 (es)
JP (1) JP2022520443A (es)
KR (1) KR20210129073A (es)
CN (1) CN113646047A (es)
AR (1) AR119691A1 (es)
AU (1) AU2020222113A1 (es)
BR (1) BR112021016059A2 (es)
CA (1) CA3130036A1 (es)
CL (1) CL2021002111A1 (es)
CO (1) CO2021010751A2 (es)
IL (1) IL285526A (es)
JO (1) JOP20200037A1 (es)
MA (1) MA54942A (es)
MX (1) MX2021009837A (es)
PE (1) PE20212322A1 (es)
SG (1) SG11202108766RA (es)
TW (1) TW202045205A (es)
UY (1) UY38587A (es)
WO (1) WO2020165912A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383105C (en) * 1999-09-24 2010-01-26 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
CN103952376A (zh) * 2008-09-24 2014-07-30 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
AU2018301395A1 (en) * 2017-07-11 2020-02-06 Universal Stabilization Technologies, Inc. Method for Preserving Biological Materials

Also Published As

Publication number Publication date
BR112021016059A2 (pt) 2021-10-13
AR119691A1 (es) 2022-01-05
KR20210129073A (ko) 2021-10-27
CL2021002111A1 (es) 2022-01-28
CA3130036A1 (en) 2020-08-20
EP3924052A1 (en) 2021-12-22
WO2020165912A1 (en) 2020-08-20
JP2022520443A (ja) 2022-03-30
UY38587A (es) 2020-09-30
US20220211837A1 (en) 2022-07-07
JOP20200037A1 (ar) 2020-08-15
TW202045205A (zh) 2020-12-16
MX2021009837A (es) 2021-09-10
IL285526A (en) 2021-09-30
PE20212322A1 (es) 2021-12-14
SG11202108766RA (en) 2021-09-29
MA54942A (fr) 2021-12-22
CN113646047A (zh) 2021-11-12
AU2020222113A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
Baz et al. H5N1 vaccines in humans
Wong et al. Traditional and new influenza vaccines
Easterbrook et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice
AU2006234304B2 (en) Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
KR102080062B1 (ko) 인플루엔자 바이러스 돌연변이체들 및 그들의 용도들
US20110171260A1 (en) Influenza dna vaccination and methods of use thereof
AR069883A1 (es) Virus de la estomatitis vesicular geneticamente modificado, composicion inmunogenica que lo comprende, metodo para producirlo, metodos para adaptar un virus para crecer en el cultivo de cedula y para proteger un mamifero contra la infeccion con un organismo patogeno
BR112012022939A2 (pt) composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
KR20090007599A (ko) 인플루엔자 바이러스 백신
Looi et al. How far have we reached in development of effective influenza vaccine?
Umar et al. Emerging threat of H9N2 viruses in poultry of Pakistan and vaccination strategy
Wohlbold et al. An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13
Nishi et al. Genetic analysis of an H5N2 highly pathogenic avian influenza virus isolated from a chicken in a live bird market in Northern Vietnam in 2012
ŠANTAK Old and new ways to combat human influenza virus
CO2021010751A2 (es) Vacuna de influenza atenuada en vivo composición y proceso de preparación de los mismos
AR085800A1 (es) Vacuna de rinitis equina
Lee et al. Cell culture-based influenza vaccines as alternatives to egg-based vaccines
Wen et al. Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs
Jiang et al. Protective efficacy of H7 subtype avian influenza DNA vaccine
CN100467591C (zh) 重组禽流感病毒毒株、其制备方法及由其制得的疫苗
KR101426407B1 (ko) 고생산성, 고면역원성, 및 무병원성 인플루엔자 바이러스 제작용 재조합 발현 벡터
Fichera et al. New strategies to overcome the drawbacks of currently available flu vaccines
US20120164175A1 (en) Novel influenza virus
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo
CN104711291B (zh) 一种预防禽流感病毒感染的新型血凝素抗原的制备及应用